Ipca Laboratories Limited

NSEI:IPCALAB Voorraadrapport

Marktkapitalisatie: ₹401.8b

Ipca Laboratories Inkomsten in het verleden

Verleden criteriumcontroles 2/6

De winst van Ipca Laboratories is gedaald met een gemiddeld jaarlijks percentage van -7.5%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 13.9%. De inkomsten zijn groeide met een gemiddeld percentage van 11.4% per jaar. Het rendement op het eigen vermogen Ipca Laboratories bedraagt 7.2% en de nettomarge bedraagt 7%.

Belangrijke informatie

-7.5%

Groei van de winst

-7.6%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie17.5%
Inkomstengroei11.4%
Rendement op eigen vermogen7.2%
Nettomarge7.0%
Volgende winstupdate14 Nov 2024

Recente prestatie-updates uit het verleden

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Jun 07
Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Recent updates

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Sep 10
Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Jun 07
Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing

May 24
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing

Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Feb 07
Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Jan 09
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Aug 20
Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Feb 28
Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Sep 20
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Aug 31
Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Jun 22
Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)

May 28
Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Mar 15
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Sep 20
These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Aug 09
Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Jun 08
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Mar 26
How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Mar 13
Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Feb 28
Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Feb 23
Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Feb 11
Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

Jan 30
Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It

Jan 15
The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It

Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly

Dec 31
Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly

Don't Ignore The Fact That This Insider Just Sold Some Shares In Ipca Laboratories Limited (NSE:IPCALAB)

Dec 16
Don't Ignore The Fact That This Insider Just Sold Some Shares In Ipca Laboratories Limited (NSE:IPCALAB)

Opbrengsten en kosten

Hoe Ipca Laboratories geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NSEI:IPCALAB Opbrengsten, kosten en inkomsten (INR Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2482,1335,76818,6240
31 Mar 2477,0595,47417,3210
31 Dec 2371,8755,64315,9230
30 Sep 2366,8064,92214,5170
30 Jun 2362,5004,91113,4500
31 Mar 2362,4814,71313,1020
31 Dec 2260,2255,25012,7790
30 Sep 2259,0706,14212,4310
30 Jun 2258,5057,20512,2040
31 Mar 2258,3058,84111,9720
31 Dec 2156,5619,15211,5550
30 Sep 2156,3559,83711,1690
30 Jun 2154,52110,00510,7510
31 Mar 2154,20711,40010,3180
31 Dec 2053,80210,64710,1350
30 Sep 2051,8339,9689,9970
30 Jun 2051,0619,2289,7720
31 Mar 2046,4996,0639,3660
31 Dec 1944,5636,1898,9110
30 Sep 1942,4965,8048,4550
30 Jun 1939,7775,0598,2540
31 Mar 1937,7504,4488,1230
31 Mar 1832,8522,3947,6040
31 Mar 1731,5621,9457,1820
31 Mar 1628,6719316,4740
31 Mar 1531,4442,5425,8720
31 Mar 1432,8184,7859,200852

Kwaliteitswinsten: IPCALAB heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (7%) IPCALAB } zijn lager dan vorig jaar (7.9%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: De winst van IPCALAB is de afgelopen 5 jaar met 7.5% per jaar gedaald.

Versnelling van de groei: De winstgroei van IPCALAB over het afgelopen jaar ( 17.4% ) overtreft het 5-jarig gemiddelde ( -7.5% per jaar).

Winst versus industrie: De winstgroei IPCALAB over het afgelopen jaar ( 17.4% ) overtrof de Pharmaceuticals -sector 19.5%.


Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 7.2% ) van IPCALAB wordt als laag beschouwd.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden